Cho Pharma Inc.

Cho Pharma Inc. is a clinical-stage biotechnology company specializing in the development of innovative medicines using advanced glycoengineering technologies. Founded in 2012 and headquartered in Taipei, Cho Pharma focuses on creating next-generation therapeutic antibodies, vaccines, and antibody-drug conjugates by leveraging its proprietary platform, CHOptimax™. The company’s research pipeline addresses severe medical needs, including refractory cancers, autoimmune diseases, and infectious diseases, with several candidates in various stages of preclinical and clinical trials. Notable investigational products include glycoengineered antibodies for cancer and autoimmune conditions, as well as novel vaccines targeting pathogens such as klebsiella pneumonia. By pioneering precise glycan modifications on biotherapeutics, Cho Pharma seeks to enhance efficacy, safety, and manufacturability compared to conventional biologic drugs. The company plays a significant role in Taiwan’s rapidly growing biotechnology sector and actively pursues global collaborations to expand access to its technologies and pipeline assets. Its contributions underscore the increasing importance of glycoscience and biopharmaceutical innovation in addressing complex health challenges.